Pivotal Life Sciences | Portfolio Company News

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Gracell Biotechnologies Acquisition Completed

February 22, 2024

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

February 13, 2024

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 02, 2024

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

December 22, 2023

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

December 21, 2023

Pivotal Life Sciences Announces the Closing of $389M for Pivotal bioVenture Partners Fund II

December 18, 2023

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

December 15, 2023

Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2

December 12, 2023

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

November 29, 2023

MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics

October 30, 2023

Arcutis Announces Pricing of $100 Million Public Offering

October 19, 2023

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

September 27, 2023

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

September 26, 2023

Study Confirming Overwhelming Reduction in Bleeding of the Dual- Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late- Breaker Oral Presentation at the American Heart Association Scientific Sessions

September 26, 2023

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

September 20, 2023

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)

September 18, 2023

1 2 3